SCHOTT Pharma AG & Co. KGaA (SHTPY)
| Market Cap | 3.88B -9.5% |
| Revenue (ttm) | 1.14B +1.8% |
| Net Income | 164.67M -3.5% |
| EPS | 1.10 -3.0% |
| Shares Out | n/a |
| PE Ratio | 23.56 |
| Forward PE | 21.87 |
| Dividend | 0.03 (0.65%) |
| Ex-Dividend Date | Feb 5, 2026 |
| Volume | 100 |
| Open | 4.370 |
| Previous Close | 4.500 |
| Day's Range | 4.370 - 4.370 |
| 52-Week Range | 4.370 - 7.650 |
| Beta | 0.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About SHTPY
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold application... [Read more]
Financial Performance
In fiscal year 2025, SHTPY's revenue was 986.21 million, an increase of 3.04% compared to the previous year's 957.09 million. Earnings were 146.45 million, a decrease of -2.16%.
Financial numbers in EUR Financial StatementsNews
SCHOTT Pharma Surges as Q3 Preliminary Figures Boost 2026 Guidance
SCHOTT Pharma outperforms expectations in Q3 2026 and raises its full-year outlook, backed by robust operations, a strong Q4 pipeline and a new key glass syringe agreement.
EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast / Full year/Results / Quarter SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue an...
SCHOTT Pharma AG & Co. KGaA Slides: Corporate presentation
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Strengthening U.S. Pharmaceutical Supply: SCHOTT Pharma Inaugurates Expanded Vial Production in Lebanon, PA
LEBANON, Pa.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass ...
SCHOTT Pharma AG & Co. KGaA Slides: Corporate presentation
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q2 2026
H1 2026 saw resilient revenue and EBITDA growth, led by DCS and high-value solutions, while DDS faced temporary headwinds due to a one-off impairment. Guidance for FY 2026 is reaffirmed, with strong order book visibility and strategic investments supporting future growth.
SCHOTT Pharma AG & Co. KGaA Slides: Q2 2026
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 13, 2026.
SCHOTT Pharma AG & Co. KGaA Quarterly report: Q2 2026
SCHOTT Pharma AG & Co. KGaA has published its Q2 2026 quarterly earnings report on May 13, 2026.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw revenue up 4.8% at constant currencies and EBITDA margin rise to 27.1%, driven by strong demand for high-value solutions. Guidance for FY 2026 is maintained, with expected revenue growth of 2%-5% and continued investment in capacity expansion.
SCHOTT Pharma AG & Co. KGaA Quarterly report: Q1 2026
SCHOTT Pharma AG & Co. KGaA has published its Q1 2026 quarterly earnings report on February 11, 2026.
SCHOTT Pharma AG & Co. KGaA Slides: Q1 2026
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 11, 2026.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q4 2025
Revenue grew 3% to EUR 986 million in 2025, with high-value solutions at 57% of sales and EBITDA margin up to 28.4%. 2026 guidance anticipates 2%-5% revenue growth and a 27% EBITDA margin, with GLP-1 and specialty vials as key drivers amid lower mRNA and vaccine demand.
SCHOTT Pharma AG & Co. KGaA Annual report: Q4 2025
SCHOTT Pharma AG & Co. KGaA has published its Q4 2025 annual report on December 11, 2025.
SCHOTT Pharma AG & Co. KGaA Annual report: Q4 2025
SCHOTT Pharma AG & Co. KGaA has published its Q4 2025 annual report on December 11, 2025.
SCHOTT Pharma AG & Co. KGaA Slides: Q4 2025
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on December 11, 2025.
SCHOTT Pharma AG & Co. KGaA Slides: Corporate presentation
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on August 19, 2025.
SCHOTT Pharma AG & Co. KGaA Earnings Call Transcript: Q3 2025
Q3 revenue grew 3% year-over-year to €256 million, with EBITDA up 11% to €83 million and a record 31.7% margin, driven by high-value solutions. FY2025 guidance is for 6% organic revenue growth and a 28% EBITDA margin, with continued investment in capacity and innovation.
SCHOTT Pharma AG & Co. KGaA Quarterly report: Q3 2025
SCHOTT Pharma AG & Co. KGaA has published its Q3 2025 quarterly earnings report on August 12, 2025.
SCHOTT Pharma AG & Co. KGaA Slides: Q3 2025
SCHOTT Pharma AG & Co. KGaA has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on August 12, 2025.